Symphogen

Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer

Retrieved on: 
Monday, July 31, 2023
Tuck School of Business, University, United States Department of the Air Force, DSM-IV codes, Cancer, Business, Head, MBA, Thermo Fisher Scientific, Sutro Biopharma, Hardpan, Janssen Pharmaceuticals, Patient, Dartmouth, Investment, CBO, SAN, Generalized tonic–clonic seizure, CFO, Air force, Neoplasm, Johnson & Johnson, Lymphocyte, Santa Barbara, Therapy, Tumor microenvironment, Economics, Faculty of Biotechnical Sciences, Pharmaceutical industry, Sarcocystis neurona, Symphogen

SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief business officer (CBO).

Key Points: 
  • SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics , a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief business officer (CBO).
  • Before joining Instil Bio, Mr. Stutz was the CFO at Tolerion, and CBO at Tioma Therapeutics.
  • Mr. Stutz earned an MBA from the Tuck School of Business at Dartmouth and a B.A.
  • in business economics, from the University of California at Santa Barbara.

Mass Spectrometry Market worth $6.8 billion | MarketsandMarkets

Retrieved on: 
Monday, June 26, 2023
Symphogen, ASP, Partnership, Cellario, Veolia Water Technologies & Solutions, Center for Cell and Gene Therapy, Table, SLIM, Mass spectrometry, Food safety, Shimadzu, SCIEX, Lipid, Structures for lossless ion manipulations, Intelligence, Unresolved complex mixture, Research, Thermo Fisher Scientific, Noetics, Proteomics, Environmental monitoring, Protein, Data analysis, Acquisition, Echo, Mass, Machine learning, PerkinElmer, Agilent Technologies, Metabolomics, Algorithm, Drug discovery, Quality control, Range, Waters Corporation, Atomic mass, Isotope, Quantitative analysis, Gene therapy, Peptide, Automation, Bruker, Software, Medical imaging, Fine chemical, Computer data storage, Uranium mining, Retail

In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.

Key Points: 
  • In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.
  • Mass Spectrometry Market – Report Highlights:
    In this report, mass spectrometry are considered, along with tables and accessories, used for healthcare applications pharmaceutical industries.
  • The study consists of the average selling price (ASP) analysis for different products in the mass spectrometry market.
  • These companies have emerged as key market players in recent years due to their products and various strategic investments undertaken in the mass spectrometry market space.

Mass Spectrometry Market worth $6.8 billion | MarketsandMarkets

Retrieved on: 
Monday, June 26, 2023
Symphogen, ASP, Partnership, Cellario, Veolia Water Technologies & Solutions, Center for Cell and Gene Therapy, Table, SLIM, Mass spectrometry, Food safety, Shimadzu, SCIEX, Lipid, Structures for lossless ion manipulations, Intelligence, Unresolved complex mixture, Research, Thermo Fisher Scientific, Noetics, Proteomics, Environmental monitoring, Protein, Data analysis, Acquisition, Echo, Mass, Machine learning, PerkinElmer, Agilent Technologies, Metabolomics, Algorithm, Drug discovery, Quality control, Range, Waters Corporation, Atomic mass, Isotope, Quantitative analysis, Gene therapy, Peptide, Automation, Bruker, Software, Medical imaging, Fine chemical, Computer data storage, Uranium mining, Retail

In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.

Key Points: 
  • In summary, the mass spectrometry market offers high sensitivity, structural characterization, versatility, quantitative analysis, selectivity, rapid analysis, and advancements in data analysis.
  • Mass Spectrometry Market – Report Highlights:
    In this report, mass spectrometry are considered, along with tables and accessories, used for healthcare applications pharmaceutical industries.
  • The study consists of the average selling price (ASP) analysis for different products in the mass spectrometry market.
  • These companies have emerged as key market players in recent years due to their products and various strategic investments undertaken in the mass spectrometry market space.

Global Functional Genomics Market Report 2023: Sector is Expected to Reach $46.24 Billion by 2033 at a CAGR of 14.04% - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Health, Genetics, Pacific Biosciences, Symphogen, DNA, BIS, Partnership, Workflow, Epigenomics, Research, Thermo Fisher Scientific, Genomics, RNA, Proteomics, Protein, Data analysis, Oxford Nanopore Technologies, Laboratory, Illumina, Inc., Metabolomics, Medicine, Growth, Region, Gene, Disease, Genome, Antibiotics

In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.

Key Points: 
  • In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.
  • The growth in the global functional genomics market is expected to be driven by its increased applications especially in targeted therapy and precision medicine.
  • Functional genomics is the study of genes and their interactions in different biological processes.
  • According to BIS Research functional genomics products are used in DNA level (epigenomics), RNA level (transcriptomics), protein level (proteomics) or metabolite level (metabolomics).

The First Women in Leadership Network to Support Diversity, Equality and Inclusion across the Life Sciences Industry launched in Denmark

Retrieved on: 
Thursday, February 9, 2023
Science, Woman, Symphogen, Novo Nordisk Foundation, Wild, EUR, Commerce, Female, Danish Chamber of Commerce, Chairperson, Management, Danish

COPPENHAGEN, Denmark, Feb. 9, 2023 /PRNewswire/ -- Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in the Danish Life Sciences industry, while promoting talent, diversity and inclusiveness. The initiative has received support from the Novo Nordisk Foundation, contributing EUR 56,000 over the next three years.

Key Points: 
  • COPPENHAGEN, Denmark, Feb. 9, 2023 /PRNewswire/ -- Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in the Danish Life Sciences industry, while promoting talent, diversity and inclusiveness.
  • The initiative has received support from the Novo Nordisk Foundation, contributing EUR 56,000 over the next three years.
  • Only 20% of executives in the largest Danish companies are women, while only 14% of these companies have a female CEO.
  • With this network we will contribute to unlocking the full talent potential in Denmark by promoting female talent and bringing it into play in Life Sciences and in society."

The First Women in Leadership Network to Support Diversity, Equality and Inclusion across the Life Sciences Industry launched in Denmark

Retrieved on: 
Thursday, February 9, 2023
Science, Woman, Symphogen, Novo Nordisk Foundation, Wild, EUR, Commerce, Female, Danish Chamber of Commerce, Chairperson, Management, Danish

COPPENHAGEN, Denmark, Feb. 9, 2023 /PRNewswire/ -- Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in the Danish Life Sciences industry, while promoting talent, diversity and inclusiveness. The initiative has received support from the Novo Nordisk Foundation, contributing EUR 56,000 over the next three years.

Key Points: 
  • COPPENHAGEN, Denmark, Feb. 9, 2023 /PRNewswire/ -- Women in Life Science Denmark (WiLD), an inspiring and science-centric not-for-profit network for women in senior positions across industry and academia launched in January 2023 to strengthen value creation in the Danish Life Sciences industry, while promoting talent, diversity and inclusiveness.
  • The initiative has received support from the Novo Nordisk Foundation, contributing EUR 56,000 over the next three years.
  • Only 20% of executives in the largest Danish companies are women, while only 14% of these companies have a female CEO.
  • With this network we will contribute to unlocking the full talent potential in Denmark by promoting female talent and bringing it into play in Life Sciences and in society."

908 Devices Records Strong Momentum in Life Sciences Sector

Retrieved on: 
Thursday, November 10, 2022
Stem Cells, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Software, Artificial Intelligence, Hardware, CPI, Private Securities Litigation Reform Act, Peptide, MIT, U.S. Securities and Exchange Commission, Intelligence, University of Washington, Boehringer Ingelheim, Nasdaq, ASMS, Symphogen, Research, Society, Fudan University, Technology, TrafFix Devices, Inc. v. Marketing Displays, Inc., Proteomics, Clemson, Oligonucleotide, SEC, Johns Hopkins University, Machine learning, AAV, Bio-Techne, Company, Genentech, Drug development, Cell, Mass spectrometry, University, American Society for Mass Spectrometry, CEO, Security (finance), MASS, Industry, Dana–Farber Cancer Institute, Pharmaceutical industry, Fine chemical

By providing our users with real-time control of critical product and process attributes, 908 Devices is empowering dramatic efficiencies throughout the drug development lifecycle.

Key Points: 
  • By providing our users with real-time control of critical product and process attributes, 908 Devices is empowering dramatic efficiencies throughout the drug development lifecycle.
  • 908 Devices gathered 175 users, in person and virtual, to share insights and successes using its devices.
  • For more information about 908 Devices life sciences capabilities, please visit www.908devices.com .
  • 908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications.

Actym Therapeutics Announces Significant Expansion of Senior Leadership

Retrieved on: 
Thursday, May 12, 2022
UC, Stanford University, Strategic planning, Chemical engineering, School, Dartmouth, UCSF, University, Business economics, Division, Cancer, Agency for Toxic Substances and Disease Registry, Tuck School of Business, Janssen Pharmaceuticals, Investment, Oregon State University, Therapy, Control, National Center for Manufacturing Sciences, Om, Johnson & Johnson, Hardpan, Board, University of California, Santa Barbara, Icahn School of Medicine at Mount Sinai, Business, SUGEN, Air force, Department, Company, Doctor of Philosophy, Director, IV, Strategy, FDA, Biotechnology, CBO, CA, Shantha Biotechnics, A-DNA, R, Economics, Patient, Business development, Sutro Biopharma, Pharmacology, M.B.A, MSAT, Bayer, United, Gilead Sciences, CEO, Pharmaceutical industry, Management, Vaxart, Technology, Symphogen

BERKELEY, Calif., May 12, 2022 /PRNewswire/ -- Actym Therapeutics,a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team.

Key Points: 
  • BERKELEY, Calif., May 12, 2022 /PRNewswire/ -- Actym Therapeutics,a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team.
  • "On behalf of the Executive Leadership Team and the Board of Directors, we are thrilled to welcome this accomplished group of leaders to Actym."
  • As Vice President, Technical Operations, Omkar will serve as a member of the Actym Executive Leadership Team and will be responsible for all aspects of technical development, manufacturing, analytical development, and quality at Actym.
  • Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer.

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Retrieved on: 
Wednesday, May 4, 2022
Board, Â, NASDAQ, ImClone Systems, GLOBE, Director, Company, Biotechnology, Ascites, Patient, Symphogen, NSCLC, DNA, MD, RA, Intention, CEO, Sustainability Accounting Standards Board, Eli Lilly, Large-cell lung carcinoma, Acquisition, Therapy, ACHL, EU

Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities.

Key Points: 
  • Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities.
  • I am delighted to join the Achilles Board of Directors at this exciting stage for the Company, commented Dr Ehmer.
  • Achilles also announced today that Derek DiRocco of RA Capital Management has resigned from the Board of Directors effective May 3, 2022.
  • Bernhard brings substantial experience across many important functions, and we are very happy to welcome him to our Board.

Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development

Retrieved on: 
Tuesday, March 1, 2022
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Thermo Fisher Scientific, Health, Fisher Scientific, Chromatography, Invitrogen, Applied Biosystems, Mass spectrometry, PPD, Laboratory, Mindful Scientific Inc., Workflow, Mab, Laboratoires Servier, Science, West Pharmaceutical Services explosion, Symphogen, Patheon, Research, CDS, Software, LC-MS/MS, Fine chemical

Most recently, the implementation of the Thermo Scientific Orbitrap Exploris MX Mass Detector allows for the highest level of data confidence and an efficient workflow, with seamless method transfer from development instruments.

Key Points: 
  • Most recently, the implementation of the Thermo Scientific Orbitrap Exploris MX Mass Detector allows for the highest level of data confidence and an efficient workflow, with seamless method transfer from development instruments.
  • This new system adds to Symphogens range of High-Resolution Accurate Mass (HRAM) mass spectrometry technologies, including the Thermo Scientific Q Exactive Plus Orbitrap Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) system and the Thermo Scientific Orbitrap Exploris 240 and 480 Mass Spectrometers .
  • The extension of our collaborative relationship with Symphogen demonstrates our continued commitment to solve tangible scientific challenges within the biopharmaceutical industry, said Eric Grumbach, director biopharma, pharma business, chromatography and mass spectrometry, Thermo Fisher.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.